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Dr Niels Voigt is professor of molecular pharmacology at the Institute of Pharmacology at the Georg-August University Göttingen. He graduated and received his MD from the University of Dresden in 2007. He worked as a postdoctoral scientist at the Institute of Pharmacology in Dresden, at the Medical Faculty Mannheim, Heidelberg University and at the Institute of Pharmacology at the Duisburg-Essen University. In 2013, he obtained the specialization in Pharmacology and Toxicology. His field of interest is the regulation of ion channels and calcium signalling in the normal and diseased heart. He has received numerous research awards e.g. With more than 30 000 attendees in 2018, the ESC congress is the world's largest cardiovascular congress. As such, it is an important event for clinicians to learn about the outcome of the latest clinical trials and guidelines. However, it also provides an ideal platform for close interaction between basic scientists and clinicians. The 'Scientists of Tomorrow' (SoTs), representing the community of young basic scientists within the ESC, 1 used this opportunity to enhance scientific interaction not only between basic scientists and clinicians, but also between young promising researchers and established leaders in the field of basic cardiovascular research. In particular, the SoTs organized six basic science sessions focused on mitochondria, calcium handling, atrial fibrillation (AF), cardiac regeneration, and caloric restriction. A special highlight this year was the CRISPR-Cas9 bootcamp where attendees could learn in hands-onexamples about practical approaches in genome editing. The SoTs used the opportunity to meet established scientist such as Ottavio Alfieri (Milan, ESC Gold Medal Awardee), Carol Ann Remme (Amsterdam, Outstanding Achievement Awardee), and Esther Lutgens (Amsterdam, Outstanding Achievement Awardee). In a Cardiovascular Research Onlife interview, they discuss about their research-but also career related questions and difficulties they faced on their way to success. 2 In this brief commentary, we would like to summarize some highlights of basic cardiovascular research that we spotted during the ESC congress in Munich. Thereby, we aim to make it easier for young scientists and clinicians to be informed about current trends and developments in basic cardiovascular research. We will also refer interested readers to recent publications, which will allow them to place the presented abstracts into context. Several basic research sessions at this year's ESC conference from August 25 to 29 in Munich were related to modern information technologies, topics such as big data, machine learning, and, especially, deep learning. New insights were obtained by application of modern experimental techniques such as CRISPR/Cas, optogenetics, single cell sequencing, or iPSC-derived cardiomyocytes. It has been demonstrated how modern technologies can facilitate translation of findings from research related to the pathophysiology of the heart into clinical applications. Several predictive models were presented that could be used to decrease experimental efforts by reducing diagnostic procedures to the most informative tests.
During one of the first sessions focusing on new therapeutic approaches in AF, the group of Daniel Pijnappels from Leiden investigated the feasibility of shock-free AF termination through lightcontrolled generation of atrial currents following local optogenetic gene therapy. Using this approach, induced AF could be terminated by applying a single light pulse over 1 s [Nyns. Local optogenetic therapy for acute shock-free termination of atrial fibrillation in vivo. FP196]. Later in the same session, our group demonstrated that the so called two poredomain potassium channel may be a potential novel target for antiarrhythmic therapy in AF. The channel isoform TASK-1 is predominantly expressed in the atria, and it is upregulated in AF patients. Reducing the expression of TASK-1 by gene therapy using adeno-associated viruses (AAVs) or pharmacological inhibition of the ion channel could significantly suppress AF in pigs with induced AF. No ventricular or proarrhythmogenic side effects were observed. Based on these results, a study will be initiated at the end of this year to test a newly Advances in cardio-and vascular protection were highlighted in the final summary session of the conference. According to Pemberton et al., brain natriuretic peptide (BNP) protects the heart from ischaemia-reperfusion injury when applied to isolated rat hearts or by intravenous treatment in living sheep before and after reperfusion injury [Pemberton. BNP signal peptide protects the heart from ischaemia-reperfusion injury. FP5292]. Another study found that intravenous injections of nanoparticles containing the toll-like receptor 4 (TLR4) antagonist TAK-242 at reperfusion significantly reduced invasion of inflammatory cells and thereby protected the myocardium from injury-related remodelling [Fujiwara. Nanoparticle-mediated delivery of toll-like receptor 4 antagonist to monocytes and ischaemic myocardium enhances cardioprotection against ischaemia-reperfusion injury in mice. FP2422]. Finally, Ioannis Akoumianakis, who has been awarded with the Young Investigator Award on Coronary Pathophysiology and Microcirculation, reported that insulin triggers vascular oxidative stress in patients with atherosclerosis. He suggests that this finding partially explain the inability of insulin treatment to improve cardiovascular outcomes in patients with moderately elevated blood glucose. Furthermore, he showed that inhibition of dipeptidyl peptidase IV (DPPIV) reversed the endothelial response to insulin, suggesting that treatment with the oral DPPIV inhibitor gliptin may be beneficial for secondary prevention in diabetic patients Several studies were based on induced pluripotent stem cells (iPSC) and genome editing methods to investigate inherited heart diseases. A humanized mouse model was developed carrying a phospholamban R14del mutation related to arrythmogenic cardiomyopathy. Mutant animals showed adrenergic-mediated ventricular tachycardia while structural heart changes were absent. CRISPR/Cas9 was applied to correct the mutation, which reversed symptoms. It was concluded that the investigated mutation is necessary and sufficient to cause the human phenotype [Raad. CRISPR/Cas9-mediated Disruption of the Human R14del Mutation Suppresses Arrhythmias in a Novel Humanized Mouse Model of Arrhythmogenic Cardiomyopathy. FP5289]. In iPSC-derived cardiomyocytes from Noonan syndrome patients, a new causal autosomal recessive mutation in LZTR1 was identified. The authors recapitulated the hypertrophic phenotype in vitro and uncovered a malfunction in cytosolic calcium handling, in particular a three-fold higher incidence of spontaneous diastolic calcium releases from the sarcoplasmic reticulum. The The winner of the young investigator award in basic science, Dr Toshiyuki Ko (Tokyo, Japan), used single cell gene sequencing of noncardiomyocytes in the heart to discover new anti-fibrosis targets. Thereby, he could show that the serine peptidase Htra3 is a central protective factor against fibrosis. Htra3 knockout mice showed increased fibrosis after transverse aortic constriction. Further experiments showed that Htra3 acts as a brake on TGF-beta signalling by cleaving TGF-beta. Cardiac Htra3 was increased in tissue samples of heart failure patients but downregulated after mechanical unloading. He concluded that HtrA3 seems to represent a critical regulator of cardiac fibrosis thereby providing a potential novel therapeutic target for heart failure [Ko.
Single-cell analysis of non-cardiomyocytes in heart reveals a critical regulator of cardiac homeostasis. FP1429]. (For further reading please see Gonzalez et al. 2018.) 6 The Cardiovascular Research journal session was focused on 'Precision medicine: The critical roles for big data and machine learning'. Benefits, possibilities and limitations of big data processing and tools for machine learning were critically discussed. In times of large and electronically available medical datasets, new techniques for efficient data processing and mathematical modelling are needed to find 'the right treatment for the right patient' and develop personalized treatment approaches. As a promising example, the SYNTAX Score 7 was reported as an approved method that is used in the clinics for predicting an optimal personalized revascularization treatment [Mamas. State of the art -Precision medicine: The critical roles for big data and machine learning. FP4345; Ahlberg. In the Highlight Session, Jeremy D. Pearson (London) pointed out that basic science represents around 10% of the scientific content of the ESC conference. He acknowledged the high quality and novelty of the scientific studies presented at the ESC congress 2018 and resumed that basic cardiovascular research will be essential to enable translation of novel treatments to clinical benefits.
